PF-Atlas › Clinical Trials › NCT05373914
RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis
Cudetaxestat · Phase 2
Registry ID
NCT05373914
Phase
Phase 2
Status
Unknown
Drug / intervention
Cudetaxestat (BLD-0409)
Sponsor
Blade Therapeutics
Start
2022-05-31
About this trial
Cudetaxestat is evaluated in NCT05373914, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Blade Therapeutics. Current status: Unknown.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05373914 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.